IMIGRAN TABLET 50mg

Product Information

Registration Status: Active

IMIGRAN TABLET 50mg is approved to be sold in Singapore with effective from 1995-10-26. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN08419P.

This product contains Sumatriptan 50mg( Equivalent to 70mg as Succinate) in the form of TABLET, FILM-COATED. It is approved for ORAL use.

This product is manufactured by GLAXOSMITHKLINE PHARMACEUTICALS S.A. in POLAND.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Sumatriptan

Description

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders. A transdermal patch version of sumatriptan is currently in phase I trials in the U.S. under the code name NP101 (NuPathe).

Indication

For the treatment of migraine attacks with or without aura.

Mechanism of Action

The 5-HT1B and 5-HT1D receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release.

Pharmacokinetics

Absorption
Approximately 15%
Distribution
* 2.7 L/kg [subcutaneous dosing]
Metabolism
Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme.
Elimination

Clearance

* 1200 mL/min [Following a 6-mg SC injection]

Toxicity

Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.

Active Ingredient/Synonyms

(3-[2-(dimethylamino)Ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide | 1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide | 3-(2-(dimethylamino)Ethyl)-N-methyl-1H-indole-5-methanesulfonamide | 3-[2-(dimethylamino)Ethyl]-N-methylindole-5-methanesulfonamide | NP101 | Sumatran | Sumatriptan | Sumatriptán | Sumatriptan Succinate | Sumatriptanum | Sumax | triptan | Sumatriptan |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank